KalVista Pharma (KALV) Stock Forecast & Price Target

KalVista Pharmaceuticals is a promising pharmaceutical company with a positive outlook due to its FDA-approved product EKTERLY for the treatment of hereditary angioedema, strong partnerships and collaborations with companies like Merck and Kaken Pharmaceutical, and impressive sales figures for 4Q25. However, the company may face third-party and financing risks in the future, as it relies on external parties for manufacturing and may require additional funding for the development and commercialization of its product candidates.

KalVista Pharmaceuticals is facing potential commercialization and financing risks as it works to develop and market its rare disease treatments, despite its promising FDA-approved product EKTERLY (sebetralstat). The recent acquisition offer from Chiesi Group may provide some financial stability, but it remains to be seen if KALV can effectively compete and become profitable in the highly competitive HAE therapy market. Additionally, the company's reliance on licensing and grant income highlights the need for continued funding and raises questions about its long-term sustainability. Given these risks, it may be prudent to hold off on investing in KALV until there is more clarity and stability in the company's financials and competitive position.